Omeros Corporation  

(Public, NASDAQ:OMER)   Watch this stock  
Find more results for OMER
12.29
+0.98 (8.66%)
Apr 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.28 - 12.47
52 week 3.77 - 14.69
Open 11.28
Vol / Avg. 0.00/506,143.00
Mkt cap 416.13M
P/E     -
Div/yield     -
EPS -1.41
Shares 33.86M
Beta 0.96
Inst. own 32%
May 5, 2014
Q1 2014 Omeros Corporation Earnings Release (Estimated) Add to calendar
Apr 9, 2014
Omeros Corporation at 13th Annual Needham Healthcare Conference
Mar 28, 2014
Omeros Corporation at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference
Mar 13, 2014
Q4 2013 Omeros Corporation Earnings Release
Mar 5, 2014
Omeros Corporation at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1091.72% -2487.25%
Operating margin -829.59% -2376.00%
EBITD margin - -3138.38%
Return on average assets -51.84% -184.63%
Return on average equity - -
Employees 75 -
CDP Score - -

Address

201 Elliott Avenue West
SEATTLE, WA 98119
United States - Map
+1-206-6765000 (Phone)
+1-206-6765005 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system. The Company develops pharmaceutical and therapeutic approaches to the management of surgical pain and inflammation, vasospasm, smooth muscle spasm, vascular restenosis and implantable surgical devices. Omeros develops products that are delivered directly to the site of tissue injury, preemptively inhibiting inflammation, pain and other problems associated with medical and surgical procedures.

Officers and directors

Gregory A. Demopulos M.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Michael A. Jacobsen Principal Financial Officer, Principal Accounting Officer
Age: 55
Bio & Compensation  - Reuters
Michael K. Inouye Vice President - Operations
Age: 55
Bio & Compensation  - Reuters
Marcia S. Kelbon J.D. Vice President - Patent, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
Thomas J. Cable Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Peter A. Demopulos M.D. Director
Age: 59
Bio & Compensation  - Reuters
Ray Aspiri Independent Director
Age: 76
Bio & Compensation  - Reuters
Arnold C. Hanish Independent Director
Age: 65
Bio & Compensation  - Reuters
Leroy E. Hood M.D., Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters